Global Pharmaceutical Packaging Equipment Market Revenue Grows at a CAGR of 5.42%

Introduction

Straits Research released its highly anticipated report, “Global Pulmonary Drug Delivery Systems Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 58.67 billion in 2025 and is projected to expand to USD 94.02 billion by 2034, registering a compound annual growth rate (CAGR) of 5.42%.

Market Dynamics

The global pulmonary drug delivery systems market is experiencing notable growth, driven by the rising prevalence of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. Increasing urbanization, air pollution, and aging populations have contributed to a higher incidence of these conditions worldwide, creating a strong demand for effective pulmonary drug delivery devices. The need for precise and efficient drug administration to the lungs encouraged investments in advanced inhalers, dry powder inhalers, and nebulizer technologies, supporting the expansion of the market.

However, the market faces a restraint in the form of high treatment and device costs. Pulmonary drug delivery systems require sophisticated design, precise particle engineering, and regulatory compliance, which collectively increase manufacturing and operational expenses. These high costs limit accessibility in low and middle-income countries and slow adoption rates among patients.

On the other hand, the market presents a considerable opportunity through the integration of digital and smart inhaler technologies. Smart devices that track dosage, monitor adherence, and provide real time feedback to patients and healthcare providers are gaining traction. Additionally, the expansion of these technologies into emerging markets with increasing respiratory disease prevalence provides substantial room for growth. This combination of technological innovation and expanding healthcare infrastructure positions the pulmonary drug delivery systems market for sustained long-term growth.

Market Highlights

• Product: The inhalers segment dominated the market in 2025.
• Application: The asthma segment is estimated to grow at the fastest pace with a CAGR of 5.93%.
• End Use: The hospitals segment dominated the market in 2025.
• Regional Insights: North America dominated the global market, accounting for 38.02% share in 2025. This growth is attributed to the widespread adoption of advanced inhalation devices.

Competitive Players

1. 3M
2. AptarGroup, Inc.
3. AstraZeneca
4. Boehringer Ingelheim GmbH
5. Briggs Healthcare
6. Chiesi Farmaceutici S.p.A.
7. Cipla Ltd.
8. Gilbert Technologies
9. GSK plc
10. Koninklijke Philips N.V.
11. Novartis AG
12. OMRON Healthcare, Inc.
13. PARI GmbH
14. Propeller Health
15. ResMed
16. Sanofi S.A.
17. Sunovion Pharma
18. Teva Pharmaceutical Industries Ltd.
19. Vectura Group
20. Others

Recent Developments

October 2025: Amneal Pharmaceuticals, Inc., received the U.S. FDA tentative approval for beclomethasone dipropionate HFA inhalation aerosol.

Segmentation

1. By Product (2026-2034)
   1. Inhalers
   2. Nebulizers
      1. Jet Nebulizers
      2. Soft-Mist Nebulizers
      3. Ultrasonic Nebulizers
2. By Application (2026-2034)
   1. Asthma
   2. Chronic Obstructive Pulmonary Disease (COPD)
   3. Allergic Rhinitis
   4. Pulmonary Arterial Hypertension
   5. Others
3. By End Use (2026-2034)
   1. Hospitals & Clinics
   2. Ambulatory Surgical Centers
   3. Homecare Settings
   4. Others